UY37214A - Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2- hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridine-2- carboxamida - Google Patents

Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2- hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridine-2- carboxamida

Info

Publication number
UY37214A
UY37214A UY0001037214A UY37214A UY37214A UY 37214 A UY37214 A UY 37214A UY 0001037214 A UY0001037214 A UY 0001037214A UY 37214 A UY37214 A UY 37214A UY 37214 A UY37214 A UY 37214A
Authority
UY
Uruguay
Prior art keywords
indazol
hidroxipropan
carboxamida
trifluorometil
methylbuty
Prior art date
Application number
UY0001037214A
Other languages
English (en)
Inventor
Johannes Platzek Dr
Tobias Thaler Dr
Nicolas Guimond Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY37214A publication Critical patent/UY37214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a las formas de N-[2-(3-Hidroxi-3-metilbutil)-6-(2-hidroxipropan- 2-il)-2H-indazol-5-il]-6-(trifluorometil)piridini-2-carboxamida, a los procesos para su preparación, a las composiciones farmacéuticas que las comprenden y a su uso en el control de trastornos.
UY0001037214A 2016-04-29 2017-04-28 Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2- hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridine-2- carboxamida UY37214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167650 2016-04-29
EP16167649 2016-04-29

Publications (1)

Publication Number Publication Date
UY37214A true UY37214A (es) 2017-11-30

Family

ID=58579196

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001037217A UY37217A (es) 2016-04-29 2017-04-28 Síntesis de indazoles
UY0001037214A UY37214A (es) 2016-04-29 2017-04-28 Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2- hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridine-2- carboxamida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001037217A UY37217A (es) 2016-04-29 2017-04-28 Síntesis de indazoles

Country Status (37)

Country Link
US (2) US10633365B2 (es)
EP (2) EP3448847A1 (es)
JP (2) JP6916207B2 (es)
KR (2) KR102379948B1 (es)
CN (3) CN109071491B (es)
AU (2) AU2017257208B2 (es)
BR (1) BR112018072247A2 (es)
CA (2) CA3022327A1 (es)
CL (2) CL2018003085A1 (es)
CO (2) CO2018011607A2 (es)
CU (1) CU24593B1 (es)
DK (1) DK3448849T3 (es)
DO (1) DOP2018000236A (es)
EA (1) EA038103B1 (es)
EC (1) ECSP18081451A (es)
ES (1) ES2801800T3 (es)
GE (1) GEP20217230B (es)
HU (1) HUE049331T2 (es)
IL (2) IL262391B (es)
JO (2) JOP20170102B1 (es)
LT (1) LT3448849T (es)
MA (1) MA44758A (es)
MX (2) MX2018013227A (es)
NI (1) NI201800111A (es)
PE (2) PE20190172A1 (es)
PH (1) PH12018502288A1 (es)
PL (1) PL3448849T3 (es)
PT (1) PT3448849T (es)
RS (1) RS60419B1 (es)
SG (2) SG11201808686VA (es)
SI (1) SI3448849T1 (es)
SV (1) SV2018005776A (es)
TN (1) TN2018000359A1 (es)
TW (3) TWI671291B (es)
UA (2) UA122882C2 (es)
UY (2) UY37217A (es)
WO (2) WO2017186700A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CA3016364A1 (en) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
MX2018013235A (es) 2016-04-29 2019-02-13 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
CN109071491B (zh) 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
BR112018074919A2 (pt) 2016-06-01 2020-11-03 Bayer Pharma Aktiengesellschaft uso de indazóis 2-substituídos para tratamento e profilaxia de doenças autoimunes.
KR102547834B1 (ko) * 2016-06-01 2023-06-26 바이엘 애니멀 헬스 게엠베하 동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸
KR20210024543A (ko) 2018-06-25 2021-03-05 치아타이 티안큉 파마수티컬 그룹 주식회사 IRAK4 억제제로서의 이소티아졸로[5,4-d]피리미딘 화합물
KR102392788B1 (ko) 2019-01-08 2022-04-28 주식회사 엘지에너지솔루션 폴더블 사이드 플레이트를 구비하는 배터리 모듈 및 그 제조 방법
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
JP5258563B2 (ja) 2006-06-29 2013-08-07 日産化学工業株式会社 αアミノ酸誘導体及びそれを有効成分として含む医薬
CA2663100A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
US20120196824A1 (en) 2009-10-09 2012-08-02 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US9073892B2 (en) 2010-12-20 2015-07-07 Merck Serono S.A. Indazolyl triazol derivatives
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2928886B1 (en) 2012-12-07 2016-11-02 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
US9126984B2 (en) * 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en) * 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
CA3016364A1 (en) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109071491B (zh) 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
MX2018013235A (es) 2016-04-29 2019-02-13 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil )etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida.
KR102547834B1 (ko) 2016-06-01 2023-06-26 바이엘 애니멀 헬스 게엠베하 동물에서의 알레르기성 및/또는 염증성 질환의 치료 및 예방에 유용한 치환된 인다졸
BR112018074919A2 (pt) 2016-06-01 2020-11-03 Bayer Pharma Aktiengesellschaft uso de indazóis 2-substituídos para tratamento e profilaxia de doenças autoimunes.

Also Published As

Publication number Publication date
PL3448849T3 (pl) 2020-12-14
AU2017257208B2 (en) 2022-01-20
AU2017256659A1 (en) 2018-10-25
KR102409105B1 (ko) 2022-06-16
TW201738233A (zh) 2017-11-01
CU20180130A7 (es) 2019-06-04
WO2017186693A1 (en) 2017-11-02
WO2017186700A1 (en) 2017-11-02
KR20180137498A (ko) 2018-12-27
EA201892407A1 (ru) 2019-05-31
CN109071491B (zh) 2020-08-21
GEP20217230B (en) 2021-03-10
JP2019514924A (ja) 2019-06-06
TWI651316B (zh) 2019-02-21
IL262413B (en) 2021-05-31
JP6821701B2 (ja) 2021-01-27
TW201738231A (zh) 2017-11-01
JOP20170101B1 (ar) 2022-03-14
US20190152944A1 (en) 2019-05-23
PH12018502288A1 (en) 2019-07-15
CA3022327A1 (en) 2017-11-02
MA44758A (fr) 2019-03-06
IL262413A (en) 2018-12-31
US10633365B2 (en) 2020-04-28
JP2019514921A (ja) 2019-06-06
RS60419B1 (sr) 2020-07-31
EP3448847A1 (en) 2019-03-06
CN112898269A (zh) 2021-06-04
EP3448849A1 (en) 2019-03-06
SG11201809172WA (en) 2018-11-29
CO2018011607A2 (es) 2018-11-22
JOP20170102B1 (ar) 2023-09-17
MX2018013232A (es) 2019-02-13
NI201800111A (es) 2019-08-29
PE20240651A1 (es) 2024-04-04
CO2018011655A2 (es) 2018-11-13
SV2018005776A (es) 2019-03-18
JP6916207B2 (ja) 2021-08-11
ES2801800T3 (es) 2021-01-13
TN2018000359A1 (en) 2020-06-15
LT3448849T (lt) 2020-09-25
CN109071491A (zh) 2018-12-21
ECSP18081451A (es) 2018-11-30
TWI671291B (zh) 2019-09-11
CA3022329A1 (en) 2017-11-02
IL262391A (en) 2018-12-31
EA038103B1 (ru) 2021-07-06
AU2017256659B2 (en) 2021-05-27
PE20190172A1 (es) 2019-02-01
UY37217A (es) 2017-11-30
PT3448849T (pt) 2020-06-30
BR112018072247A2 (pt) 2019-02-12
BR112018072213A2 (pt) 2019-02-12
US10501437B2 (en) 2019-12-10
EP3448849B1 (en) 2020-05-13
AU2017257208A1 (en) 2018-11-01
KR20190002468A (ko) 2019-01-08
US20190144420A1 (en) 2019-05-16
CN109415339A (zh) 2019-03-01
DK3448849T3 (da) 2020-06-29
KR102379948B1 (ko) 2022-03-31
CU24593B1 (es) 2022-05-11
IL262391B (en) 2022-03-01
DOP2018000236A (es) 2019-01-15
SI3448849T1 (sl) 2020-07-31
HUE049331T2 (hu) 2020-09-28
UA123550C2 (uk) 2021-04-21
MX2018013227A (es) 2019-02-13
CL2018003085A1 (es) 2019-02-15
UA122882C2 (uk) 2021-01-13
SG11201808686VA (en) 2018-11-29
TW201936599A (zh) 2019-09-16
CL2018003097A1 (es) 2019-02-15

Similar Documents

Publication Publication Date Title
DOP2018000236A (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
NI201800112A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6- (trifluorometil)piridin-2-carboxamida
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CO2018000113A2 (es) Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CO2018001756A2 (es) Concentrados en suspensión aceitosa con baja separación gravimétrica y baja viscosidad
CL2016001367A1 (es) Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).
CY1123267T1 (el) Κρυσταλλικες μορφες 2-(tpit-boytyλamino)-4-((1r,3r,4r)-3-yδpoξy-4-μεθυλοκυκλοεξυλαμινο)-πυριμιδινο-5-καρβοξαμιδιου
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2015003470A1 (es) Moduladores del receptor cxcr7.
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO2017007249A2 (es) Modificación cristalina de propanil
DK3191475T3 (da) Krystalformer af 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamid
CL2021000930A1 (es) Piridazinas novedosas
BR112017011285A2 (pt) compostos intermediários para produzir ingredientes de perfumaria
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CL2018001370A1 (es) Derivados novedosos de diamino piridina
UY37338A (es) Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida y las composiciones que los contienen

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230926